Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 3 (2021)
Review Article
Submitted: 2020-09-29
Accepted: 2020-12-28
Published online: 2021-03-12
View PDF Download PDF file Supp./Additional Files [16]
Get Citation

Trends in glioblastoma treatment research: an analysis of clinical trials and literature

Aleksander E. Łaba12, Piotr Ziółkowski1
DOI: 10.5603/PJNNS.a2021.0024
·
Pubmed: 33710606
·
Neurol Neurochir Pol 2021;55(3):269-280.
Affiliations
  1. Department of Pathology, Wroclaw Medical University, K. Marcinkowskiego 1, 50-368 Wrocław, Poland
  2. Department of Neurology, Regional Specialist Hospital, Koszarowa 5, 51-149 Wrocław, Poland

open access

Vol 55, No 3 (2021)
Review articles
Submitted: 2020-09-29
Accepted: 2020-12-28
Published online: 2021-03-12

Abstract

Introduction. Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials and peer-reviewed journal publications.

Materials and methods. Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov was analysed. Information on interventions’ mechanisms of action was obtained from AdisInsight. A PubMed search for ‘glioblastoma’ was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and analyzing data was developed by the authors.

Results. 1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified. The distribution of glioblastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having increased especially since 2006. Publications on identified treatment options comprised 32.2%. Publications on glioblastoma are cited on average 4.27 times per year. The average specificity of treatment options’ publications for glioblastoma is 6.9%.

Conclusions. Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their
scientific research output. To the best of our knowledge, no such registries have been elaborated before.

Abstract

Introduction. Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials and peer-reviewed journal publications.

Materials and methods. Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov was analysed. Information on interventions’ mechanisms of action was obtained from AdisInsight. A PubMed search for ‘glioblastoma’ was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and analyzing data was developed by the authors.

Results. 1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified. The distribution of glioblastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having increased especially since 2006. Publications on identified treatment options comprised 32.2%. Publications on glioblastoma are cited on average 4.27 times per year. The average specificity of treatment options’ publications for glioblastoma is 6.9%.

Conclusions. Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their
scientific research output. To the best of our knowledge, no such registries have been elaborated before.

Full Text:

View PDF Download PDF file Supp./Additional Files [16]
Get Citation

Keywords

glioblastoma, treatment, research, clinical trial, literature, review

Supp./Additional Files (16)
Figure S1
View
53KB
Figure S2
View
92KB
Figure S3
View
51KB
Figure S4
View
164KB
Figure S5
View
118KB
Figure S6
View
134KB
Figure S7
View
68KB
Figure S8
View
91KB
Figure S9
View
842KB
Figure S9 (additional vector - PDF - graphic)
Download
727KB
Supplementary Figures Legend
Download
12KB
Table S1
Download
23KB
Table S2
Download
14KB
Table S3
Download
18KB
Table S4
Download
24KB
Table S5
Download
23KB
About this article
Title

Trends in glioblastoma treatment research: an analysis of clinical trials and literature

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 3 (2021)

Article type

Review Article

Pages

269-280

Published online

2021-03-12

Page views

1542

Article views/downloads

839

DOI

10.5603/PJNNS.a2021.0024

Pubmed

33710606

Bibliographic record

Neurol Neurochir Pol 2021;55(3):269-280.

Keywords

glioblastoma
treatment
research
clinical trial
literature
review

Authors

Aleksander E. Łaba
Piotr Ziółkowski

References (48)
  1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2: ii1–i56.
    CrossRefPubMed
  2. Brodbelt A, Greenberg D, Winters T, et al. (UK) National Cancer Information Network Brain Tumour Group. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015; 51(4): 533–542.
    CrossRefPubMed
  3. Hansen S, Rasmussen BK, Laursen RJ, et al. Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014. J Neurooncol. 2018; 139(2): 479–489.
    CrossRefPubMed
  4. Natukka T, Raitanen J, Haapasalo H, et al. Incidence trends of adult malignant brain tumors in Finland, 1990-2016. Acta Oncol. 2019; 58(7): 990–996.
    CrossRefPubMed
  5. Sadetzki S, Zach L, Chetrit A, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008; 31(4): 264–269.
    CrossRefPubMed
  6. Dobes M, Khurana VG, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): Findings of a multicenter Australian study. Surg Neurol Int. 2011; 2: 176.
    CrossRefPubMed
  7. Cote DJ, Ostrom QT, Gittleman H, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019; 125(19): 3390–3400.
    CrossRefPubMed
  8. Muquit S, Parks R, Basu S. Socio-economic characteristics of patients with glioblastoma multiforme. J Neurooncol. 2015; 125(2): 325–329.
    CrossRefPubMed
  9. Miranda-Filho A, Piñeros M, Soerjomataram I, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017; 19(2): 270–280.
    PubMed
  10. Lee CH, Jung KW, Yoo H, et al. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010; 48(2): 145–152.
    CrossRefPubMed
  11. Tamimi AF, Tamimi I, Abdelaziz M, et al. Epidemiology of Malignant and Non-Malignant Primary Brain Tumors in Jordan. Neuroepidemiology. 2015; 45(2): 100–108.
    CrossRefPubMed
  12. Korja M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2019; 21(3): 370–379.
    CrossRefPubMed
  13. Chapman S, Azizi L, Luo Q, et al. Has the incidence of brain cancer risen in Australia since the introduction of mobile phones 29 years ago? Cancer Epidemiol . 2016; 42: 199–205.
  14. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7): 896–913.
    CrossRefPubMed
  15. Philips A, Henshaw DL, Lamburn G, et al. Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995-2015 Suggests an Adverse Environmental or Lifestyle Factor. J Environ Public Health. 2018; 2018: 7910754.
    CrossRefPubMed
  16. Young JS, Chmura SJ, Wainwright DA, et al. Management of glioblastoma in elderly patients. J Neurol Sci. 2017; 380: 250–255.
    CrossRefPubMed
  17. Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica. 2007; 114(2): 97–109.
    CrossRef
  18. IJzerman-Korevaar M, Snijders TJ, de Graeff A, et al. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. J Neurooncol. 2018; 140(3): 485–496.
    CrossRefPubMed
  19. Stensjøen AL, Solheim O, Kvistad KA, et al. Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol. 2015; 17(10): 1402–1411.
    CrossRefPubMed
  20. Starnoni D, Berthiller J, Idriceanu TM, et al. Returning to work after multimodal treatment in glioblastoma patients. Neurosurg Focus. 2018; 44(6): E17.
    CrossRefPubMed
  21. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016; 18(11): 1062–1071.
    CrossRefPubMed
  22. Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69(1): 7–34.
    CrossRef
  23. National Cancer Institute (NIH). SEER Cancer Statistics. https://seer.cancer.gov/statfacts/ (2019 Sep 8).
  24. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987–996.
    CrossRefPubMed
  25. Ostrom QT, Rubin JB, Lathia JD, et al. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018; 20(4): 576–577.
    CrossRefPubMed
  26. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6): e315–e329.
    CrossRefPubMed
  27. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015; 5: 18046.
    CrossRefPubMed
  28. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23): 2306–2316.
    CrossRefPubMed
  29. Pham TM, Sikdar KC, Cheung WY, et al. Premature Mortality Due to Malignancies of the Central Nervous System in Canada, 1980-2010. Neuroepidemiology. 2018; 50(3-4): 195–200.
    CrossRefPubMed
  30. Bianco J, Bastiancich C, Jankovski A, et al. On glioblastoma and the search for a cure: where do we stand? Cell Mol Life Sci. 2017; 74(13): 2451–2466.
    CrossRefPubMed
  31. Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129(6): 829–848.
    CrossRefPubMed
  32. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–820.
    CrossRefPubMed
  33. Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci. 2018; 8(1).
    CrossRefPubMed
  34. Cihoric N, Tsikkinis A, Minniti G, et al. Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov. Radiat Oncol. 2017; 12(1): 1.
    CrossRefPubMed
  35. Vanderbeek AM, Rahman R, Fell G, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018; 20(8): 1034–1043.
    CrossRefPubMed
  36. Zanders ED, Svensson F, Bailey DS. Therapy for glioblastoma: is it working? Drug Discov Today. 2019; 24(5): 1193–1201.
    CrossRefPubMed
  37. Nieder C, Astner ST, Grosu AL. Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. Clin Neurol Neurosurg. 2012; 114(9): 1207–1210.
    CrossRefPubMed
  38. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010; 7(9): e1000326.
    CrossRefPubMed
  39. United States National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed.
  40. National Cancer Institute Thesaurus. ncit.nci.nih.gov/ncitbrowser (2019 Aug 15).
  41. Springer. AdisInsight. https://adisinsight.springer.com ( 2019 Sep 15).
  42. Falagas ME, Pitsouni EI, Malietzis GA, et al. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008; 22(2): 338–342.
    CrossRefPubMed
  43. Elsevier. Scopus. https://www.scopus.com.
  44. Vito MRM. segmented: an R Package to Fit Regression Models with Broken-Line Relationships. http://cran.r-project.org/doc/Rnews/.
  45. Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011; 343: d2090.
    CrossRefPubMed
  46. Rich MW. Impact Factor Revisited. J Card Fail. 2017; 23(8): 579–580.
    CrossRefPubMed
  47. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med. 2013; 173(11): 972–979.
    CrossRefPubMed
  48. Cohen JF, Korevaar DA, Wang J, et al. Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev. 2015; 4: 23.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl